Table 4.
Treatment-related Adverse Effects
| Adverse Events (n = 35) | Grades 1–2 n (%) | Grades 3–4 n (%) | All Grades n (%) |
|---|---|---|---|
| Fatigue | 13 (37.1) | 2 (5.7) | 15 (42.9) |
| Hematologic | |||
| Anemia | 13 (37.1) | 13 (37.1) | |
| Leukopenia | 3 (8.6) | 4 (11.4) | 7 (20.0) |
| Lymphocytopenia | 5 (14.3) | 4 (11.4) | 9 (25.7) |
| Neutropenia | 6 (17.1) | 7 (20.0) | 13 (37.1) |
| Thrombocytopenia | 6 (17.1) | 8 (22.9) | 14 (40.0) |
| Thrombosis | |||
| Pulmonary embolism | 2 (5.7) | 2(5.7) | |
| Deep vein thrombosis | 3 (8.6) | 3 (8.6) | |
| Gastrointestinal system | |||
| Appetite loss (anorexia) | 5 (14.3) | 1 (2.9) | 6 (17.1) |
| Constipation | 4 (11.4) | 4 (11.4) | |
| Diarrhea | 1 (2.9) | 1 (2.9) | |
| Dysgeusia (taste alteration) | 4 (11.4) | 4 (11.4) | |
| Increased liver enzymes | 5 (14.3) | 2 (5.7) | 7 (20.0) |
| Increased creatinine | 4 (11.4) | 4 (11.4) | |
| Hyperglycemia | 1 (2.9) | 1 (2.9) | 2 (5.7) |
| Nausea | 12 (34.3) | 1 (2.9) | 13 (37.1) |
| Vomiting (emesis) | 9 (25.7) | 9 (25.7) | |
| Weight loss (anorexia) | 2 (5.7) | 2 (5.7) | |
| Central nervous system | |||
| Seizures | 4 (11.4) | 4 (11.4) | |
| Speech impairment | 3 (8.6) | 3 (8.6) | |
| Ataxia | 4 (11.4) | 4 (11.4) | |
| Muscle atrophy/weakness | 3 (8.6) | 1 (2.9) | 4 (11.4) |
| Neuropathy | 5 (14.3) | 5 (14.3) | |
| Cognitive disturbance | 4 (11.4) | 4 (11.4) | |
| Confusion | 3 (8.6) | 3 (8.6) | |
| Mood (depression/anxiety) | 6 (17.1) | 6 (17.1) | |
| Dizziness | 2 (5.7) | 2 (5.7) | |
| Drowsiness | 2 (5.7) | 2 (5.7) | |
| Headache | 9 | 1 (2.9) | 10 (28.6) |
| Fever | 3 (8.6) | 3 (8.6) | |
| Brain infection | 1 (2.9) | 1 (2.9) | |
| Alopecia | 10 (28.6) | 1 (2.9) | 11 (31.4) |
| Cardiovascular system | |||
| Hypertension | 1 (2.9) | 1 (2.9) | |
| Tachycardia | 1 (2.9) | 1 (2.9) | |
| Respiratory system | |||
| Coughing | 1 (2.9) | 1 (2.9) | |
| Dyspnea | 3 (8.6) | 3 (8.6) | |
| Shortness of breath on exertion | 1 (2.9) | 1 (2.9) | |